Table 1 KU-174 Activity Across NCI-60 Human Tumor Cell Lines

CCRF-CEM

0.63

786-0

73.59

LOX-IMVI

9.59

COLO-205

0.63

HL-60(TB)

0.44

A498

83.68

MALME-3M

41.99

HCC-2998

42.97

K-562

23.12

ACHN

47.1

M14

-21.95

HCT-116

21.97

MOLT-4

-21.98

CAKI-1

71.91

MDA-MB-435

-17.38

HCT-15

32.2

RPMI-8226

-44.19

RXF-393

105.66

SK-MEL-2

41.67

HT29

66.64

SR

28.61

SN12C

63.5

SK-MEL-28

21.39

KM12

-45.47

TK-10

14.99

SK-MEL-5

-73.95

SW-620

38.13

UO-31

18.75

UACC-257

-39.68

UACC-62

-27.18

NSC-Lung Cancer

CNS Cancer

Ovarian Cancer

Breast Cancer

A549/ATCC

4.66

SF-268

43.3

IGROV1

28.24

MCF7

5.74

EKVX

66.17

SF-295

43.01

OVCAR-3

14

MDA-MB-231

81.66

HOP-62

0.11

SF-539

77.23

OVCAR-4

1.21

HS-578T

51.84

NCI-H23

-21.22

SNB-19

72.87

OVCAR-5

103.07

BT-549

24.27

NCI-H322M

69.89

SNB-75

81.1

OVCAR-8

-13.39

T-47D

-27.58

NCI-H460

25.82

U251

38.81

NCI/ADR-RES

-5.97

MDA-MB-468

9.61

NCI-H522

2.5

SK-OV-3

98.1

Prostate Cancer

PC-3

0.46

DU-145

51.79